What's Happening?
Researchers from the University of Barcelona have found that combining two cardiovascular drugs, pemafibrate and telmisartan, may effectively treat metabolic dysfunction-associated steatotic liver disease (MASLD), a common liver condition in the U.S. affecting 25% of adults. The study demonstrated that these drugs reduced fat accumulation in liver cells in laboratory animal models. Pemafibrate and telmisartan, already used for other conditions, have complementary mechanisms that reduce liver lipids and cardiovascular risk. This combination therapy could offer a new strategy for treating MASLD, which is often linked to lifestyle factors such as diet and exercise.
Why It's Important?
MASLD is a prevalent condition with significant health implications, including increased risk of liver damage and cardiovascular disease. Current treatments are limited, and lifestyle changes alone are often insufficient. The study's findings suggest that using existing cardiovascular drugs could provide an effective treatment option, potentially reducing the progression of liver disease and associated health risks. This approach could lead to better management of MASLD, improving patient outcomes and reducing healthcare costs related to liver disease complications.
What's Next?
Clinical trials are needed to determine the efficacy and safety of this drug combination in humans. If successful, this treatment could be integrated into standard care for MASLD, offering a new option for patients who struggle with lifestyle modifications. Researchers are also exploring the potential of these drugs in treating more advanced stages of liver disease, such as fibrosis. Continued research will focus on understanding the mechanisms by which these drugs affect liver health and their long-term impact on disease progression.
